Medical Science News

RSS

Researchers determine public attitudes towards monkeypox infections

Researchers assessed the attitudes of the general US population towards monkeypox infections.

27 Jun 2022

The association between handgrip strength and dementia risk in a UK population of middle-aged adults

Researchers analyzed the correlations between HGS, dementia, and neurocognitive outcomes among males and females from the United Kingdom.

27 Jun 2022

Model-based evidence shows SARS-CoV-2 vaccine boosters should be provided for those eligible ahead of winter

Researchers assessed the SARS-CoV-2 vaccination booster approaches in the face of arising SARS-CoV-2 variants in Europe.

27 Jun 2022

Comparison of genome sequences of SARS-CoV-2 and other coronaviruses

Researchers compared the genomic sequence of SARS-CoV-2 and that of different coronaviruses.

27 Jun 2022

Antigenic differences between early SARS-CoV-2 variants

Researchers used antigenic cartography to quantify and visualize antigenic differences between multiple SARS‐CoV‐2 variants.

27 Jun 2022

Persistent fatigue post-COVID-19 in pregnant women

Researchers determine the factors and time duration associated with fatigue for pregnant women who had positive SARS-CoV-2 serology during delivery.

27 Jun 2022

Does fecal viral excretion provide insights into on GI symptoms of COVID-19?

Researchers discuss the physiopathological mechanisms associated with digestive symptoms associated with COVID-19.

27 Jun 2022

The impact of cannabis use on COPD and COVID-19

Researchers evaluated the effects of smoking cannabis on COVID-19 test positivity.

27 Jun 2022

C-reactive protein levels predict ED risk

A recent meta-analysis aimed to describe the relationship between C-reactive protein levels and erectile dysfunction.

27 Jun 2022

Bisphosphonates appear to improve COVID-19 exposure outcomes

A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022